Compare XLO & FCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XLO | FCO |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.4M | 41.4M |
| IPO Year | 2021 | 1994 |
| Metric | XLO | FCO |
|---|---|---|
| Price | $8.63 | $3.15 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $28.00 | N/A |
| AVG Volume (30 Days) | ★ 186.9K | 131.4K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,766,000.00 | N/A |
| Revenue This Year | $88.66 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 589.88 | N/A |
| 52 Week Low | $0.46 | $2.73 |
| 52 Week High | $9.25 | $6.77 |
| Indicator | XLO | FCO |
|---|---|---|
| Relative Strength Index (RSI) | 86.23 | 51.10 |
| Support Level | $0.63 | $2.85 |
| Resistance Level | $9.25 | $3.30 |
| Average True Range (ATR) | 0.60 | 0.13 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 70.82 | 52.52 |
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories: Developed Markets, Investment Grade Developing Markets, and Sub-Investment Grade Developing Markets.